Phytopharm is a development stage pharmaceutical company developing novel treatments targeting diseases with high levels of unmet need. Our lead series of compounds, the Sapogenins (including Cogane™ and Myogane™), has the potential to be a new class of therapy for neurodegenerative diseases including Parkinson’s disease,  amyotrophic lateral sclerosis (ALS) and glaucoma.

Phytopharm operates as a virtual company ensuring the majority of our financial resources are focussed on our pharmaceutical pipeline. We utilise a network of scientific and clinical experts to help guide our development projects with our experienced pharmaceutical managers overseeing operations.

Phytopharm is listed on the London Stock Exchange main list (LSE: PYM).

IMPORTANT NEWS on Phase II Clinical Study of Cogane™

For more information on our ongoing phase II clinical study of Cogane™ in Parkinson's disease CONFIDENT-PD please click here